respiratori
viru
infect
rvi
pose
threat
children
undergo
hematopoiet
stem
cell
transplant
hsct
era
sensit
molecular
diagnost
incid
outcom
hsct
recipi
hospit
rvi
hrvi
well
describ
retrospect
observ
cohort
pediatr
hsct
recipi
januari
june
assembl
us
pediatr
transplant
center
medic
chart
review
hrvi
event
within
year
transplant
hrvi
diagnosi
requir
respiratori
sign
symptom
plu
viral
detect
human
rhinovirusenteroviru
human
metapneumoviru
influenza
parainfluenza
coronavirus
andor
respiratori
syncyti
viru
incid
hrvi
calcul
associ
baselin
hsct
factor
subsequ
pulmonari
complic
death
assess
result
among
hsct
recipi
acquir
least
hrvi
within
year
transplant
median
age
patient
hrvi
lower
patient
without
hrvi
vs
year
p
among
patient
first
hrvi
requir
respiratori
support
suffer
signific
pulmonari
sequela
allcaus
attribut
casefat
rate
within
month
hrvi
onset
respect
multivari
logist
regress
reveal
hrvi
onset
within
day
hsct
steroid
use
day
hrvi
onset
need
respiratori
support
hrvi
onset
associ
subsequ
morbid
death
conclus
result
multicent
cohort
studi
suggest
hrvi
rel
common
pediatr
hsct
recipi
contribut
signific
morbid
death
data
help
inform
intervent
studi
specif
viral
pathogen
viral
pathogen
common
sourc
pediatr
respiratori
ill
although
respiratori
viral
infect
rvi
gener
pediatr
popul
often
mild
potenti
result
signific
morbid
death
children
compromis
immun
system
pediatr
hematopoiet
stem
cell
transplant
hsct
recipi
particular
risk
poor
outcom
rvi
given
extent
durat
immunosuppress
although
effect
rvi
hsct
recipi
review
data
specif
pediatr
hsct
recipi
limit
small
singlecent
studi
rel
short
followup
time
avail
molecular
diagnost
identifi
rvi
hsct
recipi
mani
pediatr
center
repres
import
opportun
defin
contemporari
epidemiolog
outcom
rvi
pediatr
hsct
recipi
conduct
multicent
retrospect
studi
defin
incid
outcom
hospit
rvi
hrvi
larg
pediatr
cohort
first
year
hsct
result
inform
clinician
risk
hrvi
highrisk
popul
assist
design
conduct
futur
prospect
studi
compar
effect
current
newli
avail
antivir
therapi
prevent
strategi
multicent
retrospect
observ
cohort
studi
evalu
pediatr
hsct
recipi
us
pediatr
academ
institut
januari
june
tabl
studi
protocol
approv
institut
review
board
institut
cohort
inclus
patient
underw
allogen
autolog
hsct
indic
cohort
limit
children
year
age
time
hsct
hsct
recipi
follow
day
transplant
day
receipt
transplant
death
loss
followup
primari
outcom
occurr
hrvi
associ
inpati
admiss
within
day
hsct
definit
hrvi
requir
posit
result
respiratori
viral
pathogen
respiratori
specimen
obtain
via
nasal
swab
wash
aspir
nasopharyng
swab
sputum
tracheal
aspir
deep
bronchial
wash
bronchoalveolar
wash
document
clinic
sign
symptom
respiratori
ill
includ
cough
rhinorrhea
andor
increas
work
breath
within
hour
posit
respiratori
viral
test
includ
respiratori
pathogen
human
metapneumoviru
hmpv
influenza
parainfluenza
piv
respiratori
syncyti
viru
rsv
rhinovirusenteroviru
rhv
coronaviru
studi
focus
viral
pathogen
specif
respiratori
tract
adenoviru
exclud
purpos
clinic
spectrum
adenoviru
diseas
hsct
recipi
broad
diagnost
test
use
center
studi
period
list
tabl
pathogen
record
viru
detect
given
hrvi
episod
patient
hrvi
event
involv
pathogen
first
episod
includ
unless
subsequ
episod
occur
day
first
one
least
neg
test
viru
interim
patient
met
hrvi
criteria
date
hrvi
onset
day
respiratori
viral
test
order
patient
document
hrvi
follow
month
onset
assess
subsequ
need
respiratori
support
occurr
pulmonari
complic
identifi
death
respiratori
support
defin
need
supplement
oxygen
bilevel
continu
airway
pressur
convent
mechan
ventil
highfrequ
oscil
ventil
extracorpor
membran
oxygen
ecmo
pulmonari
complic
identifi
classifi
need
tracheostomi
diagnosi
subacut
chronic
pulmonari
sequela
bronchiol
obliteran
anoth
pulmonari
complic
specifi
death
occur
within
month
hrvi
onset
assess
attribut
death
attribut
viral
pathogen
sign
symptom
hrvi
improv
death
sign
symptom
consid
potenti
contributori
death
attribut
like
possibl
like
assess
perform
central
review
committe
review
deidentifi
summari
circumst
surround
patient
death
investig
train
research
assist
site
retrospect
abstract
electron
medic
record
data
element
identifi
priori
includ
demograph
pretranspl
transplant
perirvi
variabl
directli
central
redcap
electron
databas
host
duke
univers
primari
aim
studi
determin
incid
hrvi
event
cohort
pediatr
hsct
recipi
rvi
event
result
inpati
admiss
diagnos
inpati
admiss
includ
incid
hrvi
cohort
hsct
recipi
determin
consid
includ
rvi
pathogen
hmpv
influenza
piv
rsv
rhv
coronaviru
univari
logist
regress
analys
perform
assess
associ
variou
baselin
factor
time
transplant
subsequ
develop
hrvi
secondari
aim
studi
determin
frequenc
pulmonari
complic
allcaus
attribut
casefat
rate
hrvi
onset
casefat
rate
calcul
proport
patient
hrvi
die
within
month
rvi
onset
last
multivari
analys
perform
subset
patient
least
hrvi
identifi
risk
factor
present
time
first
hrvi
associ
subsequ
need
respiratori
support
pulmonari
complic
death
month
rvionset
period
follow
factor
evalu
hypothes
priori
potenti
associ
outcom
interest
age
race
need
respiratori
support
time
hrvi
diagnosi
previou
histori
chronic
lung
diseas
receipt
tcelldeplet
hsct
receipt
recent
immunosuppress
therapi
captur
steroid
nonsteroidcontain
therapi
receipt
immunoglobulin
g
week
occurr
rvi
variabl
assess
univari
logist
regress
analys
multivari
logist
regress
model
includ
age
race
factor
found
associ
outcom
interest
univari
analysi
p
statist
calcul
perform
use
stata
stata
corp
colleg
station
tx
studi
period
particip
institut
hsct
recipi
year
age
identifi
number
patient
center
rang
tabl
data
avail
patient
entir
studi
period
death
minor
patient
lost
followup
complet
captur
within
year
transplant
patient
diagnos
rvi
manag
inpati
set
incid
rate
least
hrvi
similar
allogen
autolog
hsct
recipi
vs
respect
p
tabl
list
baselin
characterist
entir
cohort
patient
without
diagnosi
hrvi
within
year
transplant
univari
analys
younger
age
associ
increas
risk
hrvi
vs
year
respect
p
neither
donor
type
tcelldeplet
statu
associ
increas
risk
hrvi
transplant
median
time
hsct
first
hrvi
onset
day
interquartil
rang
day
rhv
common
viru
follow
piv
rsv
tabl
coronaviru
detect
infrequ
note
diagnost
test
coronaviru
avail
institut
studi
period
tabl
clinic
sign
present
limit
upper
respiratori
tract
major
patient
howev
significantli
like
find
evid
lower
respiratori
tract
involv
present
children
hmpv
pathogen
vs
respect
p
fever
within
hour
ill
onset
common
except
influenzaand
hmpvassoci
event
presenc
chronic
lung
diseas
need
mechan
respiratori
support
treatment
intens
care
unit
renal
replac
therapi
ill
onset
rel
rare
signific
proport
patient
receiv
immunosuppress
agent
graftversushost
diseas
gvhd
therapi
week
hrvi
onset
specif
steroid
exposur
present
children
week
lead
hrvi
neutropenia
absolut
neutrophil
count
cell
per
ml
lymphopenia
absolut
lymphocyt
count
alc
cell
per
ml
commonli
present
week
hrvi
onset
effect
hrvi
period
onset
ill
assess
tabl
among
first
hrvi
event
type
respiratori
support
requir
children
support
limit
supplement
oxygen
patient
patient
experienc
hrvi
requir
convent
mechan
ventil
highfrequ
oscil
ventil
ecmo
posthrvi
cours
complic
signific
pulmonari
sequela
patient
includ
subacut
chronic
process
among
subset
allogen
hsct
recipi
hrvi
found
newonset
gvhd
within
month
hrvi
onset
thirti
death
occur
within
month
hrvi
onset
occur
first
rvi
event
result
allcaus
casefat
rate
allcaus
casefat
rate
rang
depend
viral
pathogen
highest
rate
patient
hmpv
death
first
hrvi
event
deem
like
possibl
like
attribut
rvi
respect
yield
attribut
casefat
rate
supplementari
tabl
provid
time
death
first
hrvi
onset
day
transplant
found
death
first
day
hrvi
death
day
hrvi
remain
death
occur
day
rvi
onset
multivari
logist
regress
model
establish
determin
associ
variou
factor
present
hrvi
onset
subsequ
need
respiratori
support
pulmonari
complic
allcaus
casefat
rate
tabl
limit
contemporari
data
defin
impact
rvi
pediatr
hsct
recipi
exist
et
al
assembl
retrospect
singlecent
us
cohort
pediatr
hsct
recipi
report
rvi
incid
rate
within
year
transplant
anoth
singlecent
cohort
pediatr
hsct
recipi
korea
rvi
incid
within
day
hsct
wherea
larger
singlecent
cohort
canada
rvi
incid
within
day
transplant
note
rvi
rate
singlecent
studi
lower
incid
hrvi
cohort
howev
studi
document
rate
within
month
transplant
make
difficult
compar
rate
accur
addit
criteria
respiratori
test
specif
respiratori
pathogen
consid
relianc
less
sensit
nonmolecular
diagnost
test
like
contribut
differ
rvi
rate
previou
report
given
studi
larg
sampl
size
fact
definit
rvi
requir
inpati
admiss
clinic
sign
symptom
polymeras
chain
reaction
pcr
posit
respiratori
specimen
hrvi
incid
rate
repres
reason
estim
contemporari
burden
rvi
associ
inpati
admiss
pediatr
hsct
recipi
nonetheless
estim
hrvi
incid
might
underestim
actual
incid
etiolog
underestim
multifactori
includ
variat
pcr
diagnost
accord
site
eg
site
test
viru
eg
coronaviru
studi
period
variat
threshold
perform
viral
diagnost
test
patient
present
symptomat
respiratori
ill
addit
patient
might
evalu
rvi
outpati
set
site
remot
transplant
center
median
time
hsct
hrvi
onset
day
rvi
event
variat
among
viral
pathogen
note
median
time
onset
coronaviru
rhv
piv
rsv
shorter
time
onset
influenza
hmpv
longer
durat
transplant
day
hrvi
onset
might
bias
prefer
perform
transplant
children
summer
possibl
thu
pathogen
viral
season
start
summer
fall
eg
piv
rsv
would
seem
shorter
median
time
onset
virus
season
onset
later
winter
eg
influenza
hmpv
document
month
transplant
institut
review
board
constraint
confirm
supposit
addit
although
major
hrvi
event
cohort
present
first
day
hsct
infect
occur
day
therefor
clinician
awar
risk
signific
hrvi
event
persist
well
beyond
first
day
transplant
period
hrvi
onset
afflict
patient
frequent
requir
respiratori
support
need
supplement
oxygen
bilevel
continu
airway
pressur
mechan
ventil
ecmo
pulmonari
complic
followup
period
note
children
patient
die
within
month
hrvi
onset
furthermor
allogen
hsct
recipi
develop
newonset
gvhd
within
month
hrvi
rate
gvhd
similar
rate
report
gener
pediatr
allogen
hsct
recipi
although
fatal
incid
hrvi
event
like
possibl
result
rvi
possibl
rvi
contribut
indirectli
remain
death
find
consist
previou
smaller
cohort
rvi
associ
allcaus
case
fatal
attribut
rvi
multivari
model
aim
identifi
factor
known
time
hrvi
onset
might
independ
portend
poor
outcom
patient
expos
steroid
day
hrvi
onset
time
like
experi
pulmonari
complic
time
like
die
followup
period
although
latter
result
reach
statist
signific
associ
steroid
exposur
link
previous
poor
outcom
adult
patient
hmpv
rsv
piv
pediatr
patient
piv
interest
recent
exposur
nonsteroid
immunosuppress
therapi
associ
wors
outcom
multivari
model
measur
inclus
heterogen
group
agent
administ
gvhd
prophylaxi
treatment
group
agent
singl
variabl
might
limit
abil
detect
associ
specif
immunosuppress
agent
previou
studi
associ
lymphopenia
rvi
onset
progress
lower
respiratori
tract
diseas
death
adult
children
rsv
influenza
piv
although
children
cohort
lymphopen
alc
cell
per
ml
hrvi
onset
alc
avail
hrvi
event
thu
could
assess
risk
factor
poor
outcom
data
tcelldeplet
statu
avail
consid
model
howev
cell
deplet
stem
cell
product
associ
subsequ
need
respiratori
support
pulmonari
complic
death
within
month
hrvi
onset
interest
hrvi
onset
within
first
day
hsct
associ
increas
need
respiratori
support
subsequ
month
earli
rvi
onset
associ
pulmonari
complic
death
need
respiratori
support
onset
hrvi
associ
increas
risk
subsequ
pulmonari
complic
death
similar
result
adult
hsct
recipi
rsv
report
although
neither
time
hrvi
onset
rel
hsct
need
respiratori
support
hrvi
onset
modifi
factor
knowledg
associ
inform
patientspecif
prognosi
discuss
beyond
limit
alreadi
mention
addit
limit
studi
worth
note
first
multivari
model
viral
pathogen
consid
equal
term
potenti
contribut
morbid
death
period
rvi
onset
particular
rhinoviru
common
pathogen
abil
diagnos
acut
rhv
diseas
challeng
potenti
prolong
rhv
viral
detect
host
notabl
pulmonari
complic
relat
rhv
infect
includ
need
oxygen
support
pressur
support
mechan
ventil
seem
occur
rate
similar
found
respiratori
infect
caus
rsv
piv
hmpv
futur
analys
focu
model
specif
pathogen
howev
subanalys
would
limit
event
second
collect
detail
data
patient
hsct
cohort
without
rvi
instead
chose
focu
subset
patient
diagnos
rvi
therefor
multivari
analys
focus
assess
factor
contribut
poor
outcom
among
patient
rvi
unabl
assess
factor
gvhd
therapi
monthli
intraven
immunoglobulin
administr
might
increas
reduc
risk
sustain
rvi
posthsct
period
third
data
regard
util
specif
antivir
therapi
neuraminidas
inhibitor
investig
sialidas
fusion
protein
ribavirin
intraven
immunoglobulin
collect
howev
small
number
patient
receiv
therapi
specif
viru
possibl
assess
compar
effect
agent
last
studi
definit
hrvi
requir
presenc
respiratori
symptom
requir
would
result
lack
detect
rvi
event
present
nonspecif
symptom
fever
thu
potenti
underestim
rvi
patient
popul
conclus
result
larg
multicent
cohort
suggest
burden
rvi
among
pediatr
hsct
recipi
rel
high
result
signific
morbid
death
identif
independ
risk
factor
recent
steroid
exposur
rvi
onset
within
day
hsct
respiratori
statu
rvi
onset
provid
opportun
inform
prognost
discuss
clinician
patient
famili
furthermor
epidemiolog
respiratori
viral
pathogen
provid
baselin
inform
inform
feasibl
futur
therapeut
clinic
trial
highlight
need
effect
prevent
intervent
vulner
popul
supplementari
materi
avail
journal
pediatr
infecti
diseas
societi
onlin
